Greensboro CRS – ACTG Network

Location	Wendover Medical Center, 301 East Wendover Avenue, Suite 111 Greensboro, NC 27401 United States of America www.conehealth-rcid.com
CRS Coordinator	Kim Epperson kim.epperson@conehealth.com 336-832-3262
CRS Leader	Cornelius Van Dam cornelius.vandam@conehealth.com 336-832-8560
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5332: REPRIEVE Trial A5345: HIV Rebound & Control Biomarkers A5354: Early ART in Acute HIV A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5359: The LATITUDE Study A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B